Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.

Related Keywords

Florida ,United States ,Tampa ,Massachusetts ,Eric Padron ,Aleksandr Lazaryan ,David Sallman ,Gabrielas Hobbs ,Andrew Kuykendall ,Moffitt Cancer Center ,Research Consortium ,Science Summit ,Malignant Hematology ,Massachusetts General Hospital ,Moffitt Cancer ,Rami Komrokji ,Patients With Myelofibrosis ,D ,Jak Inhibitors In Myelofibrosis ,Bph ,Phd ,